Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
91.92 CHF | +0.20% | -2.09% | +8.32% |
11:15am | Novartis: positive phase III results in C3G | CF |
10:15am | Novartis: presented results for kidney disease | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+8.32% | 205B | |
+38.51% | 727B | |
+32.07% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
-5.64% | 203B | |
+6.19% | 164B | |
+0.31% | 164B |
- Stock Market
- Equities
- NOVN Stock
- News Novartis AG
- Novartis to Buy Rare Disease-focused Chinook Therapeutics for $3.5 Billion